Navigation Links
Research identifies successful new treatment for Hodgkin's lymphoma, reduces long-term risks
Date:7/13/2009

PROVIDENCE, RI New research led by Cindy Schwartz, MD, of Hasbro Children's Hospital has identified a new chemotherapy regimen for pediatric Hodgkin lymphoma (HL) patients. The new treatment enhances efficacy through dose-dense drug delivery while simultaneously reducing the long-term risks presented by high cumulative dose chemotherapy. Schwartz and the researchers of the Children's Oncology Group have published their findings in the journal Blood (posted in an online first edition).

The Children's Oncology Group's Hodgkin Lymphoma Committee, led by Schwartz, director of pediatric hematology/oncology at Hasbro Children's Hospital, recognized that treatment for HL in the United States was not being treated with the most modern treatment models, in large part because it was one of the first malignancies for which a curative chemotherapy regimen was developed.

Schwartz says, "For decades, the chemotherapy regimens known as MOPP and ABVD had been the standard treatment options for these patients. However, while they yielded excellent survival rates, they often resulted in long-term effects from toxicity, including infertility, second malignancy and cardiopulmonary toxicity. With the new treatment paradigm we've developed, in essence, we've been able to cure the cancer while reducing the risk of long-term effects on our patients."

The group designed a new chemotherapy treatment known as ABVE-PC, combining six different drugs into one "dose-dense" regimen that could limit the cumulative doses of each drug below the recognized thresholds known for resulting in long-term toxicity. Their goal was to reach a rapid early response (RER) in order to further reduce cumulative therapy and to thereby increase event-free survival (EFS). They also combined the chemotherapy treatment with low dose radiation following the completion of the ABVE-PC cycles.

The treatment developed by the researchers was unique given that its focus was
'/>"/>

Contact: Nancy Cawley Jean
njean@lifespan.org
Lifespan
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Arizona researchers to sequence West African rice strain
2. Promising medical trainees receive funding to pursue research in hematology
3. Promising hematologists begin year-long program to pursue careers in clinical research
4. Grant encourages protected research time for medical fellows
5. Six Researchers to Receive Prestigious Awards from the American Society of Hematology
6. 2009 recipient of minority scholar award begins clinical research on leukemia
7. Six Scientists Receive Awards for Contributions to Alzheimers Disease Research
8. 6 scientists receive awards for contributions to Alzheimers disease research
9. Mount Sinai researchers find new Alzheimers disease treatment promising
10. NOSCAR increases NOTES research with Olympus Medical Systems Corporation grant
11. NOSCAR(R) Increases NOTES(R) Research with Olympus Medical Systems Corporation Grant
Post Your Comments:
*Name:
*Comment:
*Email: